The next triggers in Covid-19 vaccine development
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Moderna shows the value of bulk-buying
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
